Definium Therapeutics, Inc.

NASDAQ:DFTX

Biotechnology

Healthcare
$29.12 -1.67%

-$0.41 today

Market cap
$3.99B
Beta
2.38
P/E (TTM)
-11.0
EPS (TTM)
-$2.18
52W Low $12.88High $26.15

Volume 1.91M

Average 2.67M

DFTX Accounts Receivables

Cash effect of the change in amounts owed by customers; growing receivables consume cash.

Definium Therapeutics, Inc.NASDAQ: DFTX

Accounts Receivables · Q3 FY2026 · quarter ended Sep 2026

Accounts receivables outflow grows to $0

Q3 FY2026 accounts receivables was $0, compared with $0 a year earlier. Trailing-twelve-month accounts receivables was $0.

Context

  • Accounts receivables increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly accounts receivables holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterSep 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
LTMSep 2026
$0— YoY
Accounts Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Accounts Receivables history

USD · from the cash flow

Latest · FY2025
0 USD
Year-over-year change
—

Accounts Receivables vs competitors

How DFTX compares with its peers on the latest reported figures

  • Peers report in different currencies, so accounts receivables is compared through growth and share of revenue rather than absolute size.
DFTX Competitors
Accounts Receivables for DFTX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
AXSMAxsome Therapeutics, Inc.LTM Jun 2026$78.63M USD+0.2%+29.8%10.1%
LBRXLB Pharmaceuticals Inc Common StockLTM Mar 2026$205K USD———
ATHEAlterity Therapeutics LimitedFY2025A$104.07K AUD-97.7%—1.9%
RAPPRapport Therapeutics, Inc. Common StockLTM Mar 2026$58K USD——0.3%
DFTXDefinium Therapeutics, Inc.LTM Sep 2026$0 USD———
PRAXPraxis Precision Medicines, Inc.LTM Sep 2026$0 USD———
GHRSGH Research PLCLTM Mar 2026$0 USD———
ANROAlto Neuroscience, Inc.LTM Mar 2026$0 USD———
MPLTMapLight Therapeutics, Inc.LTM Mar 2026$0 USD———
NERVMinerva Neurosciences, Inc.LTM Jun 2026$0 USD———
NMRANeumora Therapeutics, Inc. Common StockLTM Mar 2026$0 USD———
Peer median (excluding DFTX) —-48.8%+29.8%1.9%

Competitors are the stored peer set for DFTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(93.04M)(56.8M)(95.73M)(108.68M)(183.79M)
Depreciation & Amortization2.62M3.18M3.16M527K0
Deferred Income Tax(1.16M)0(2.03M)00
Stock-Based Compensation42.72M13.71M15.49M16.91M20.1M
Change in Working Capital1.88M(3.78M)6.28M(3.34M)9.44M
Accounts Receivables00000
Inventory00000
Accounts Payables1.28M(2.06M)2.03M(2.13M)3.34M
Other Working Capital598K(1.73M)4.26M(1.22M)6.1M
Other Non-Cash Items1.16M(6.45M)8.46M15.45M22.7M
Operating Cash Flow(45.82M)(50.14M)(64.37M)(79.13M)(131.56M)
Capital Expenditures00000
Acquisitions (Net)(297K)0000
Purchases of Investments0000(268.36M)
Sales of Investments0000116.75M
Other Investing Activities00000
Investing Cash Flow(297K)000(151.61M)
Debt Repayment0014.16M10.86M20M
Common Stock Issued81.92M42.3M7.53M250M259.9M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities16.9M16.75M163K(7.66M)(12.63M)
Financing Cash Flow98.82M59.05M21.85M253.2M267.27M
Effect of Forex Changes742K(309K)79K(30K)(7K)
Net Change in Cash53.45M8.6M(42.44M)174.04M(15.9M)
Free Cash Flow(45.82M)(50.14M)(64.37M)(79.13M)(131.56M)

Definium Therapeutics, Inc.

NASDAQ:DFTX

Intrinsic Alpha fair value

Locked

Current Price

$29.12

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.